disease: advances in clinical management and treatments.
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive
Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.
However, although the transmission of DENV was demonstrated, the patient's death was probably caused by hepatic veno-occlusive
disease and toxic enterocolitis related to the conditioning regimen.
disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia.
Gentium recently filed a marketing authorization application with the European Medicines Agency (EMA) for the prevention and treatment of hepatic veno-occlusive
disease (VOD) in adults and children undergoing stem-cell transplantation therapy.
Individualized therapeutic drug monitoring must be performed to ensure that busulfan concentrations are optimal for treatment and to reduce the risk for graft rejection, disease relapse, and sinusoidal obstruction syndrome (SOS), previously known as veno-occlusive
The biopharmaceutical firm was testing the use of the drug, defibrotide, for preventing veno-occlusive
disease (VOD) in pediatric patients who were at high risk.
Key words: Pulmonary veno-occlusive
disease, pulmonary capillary hemangiomatosis, portopulmonary hypertension, HIV associated PAH
Hepatic sinusoidal obstruction syndrome: a toxic injury to sinusoidal endothelial cells causing a cascade of events, including compromised blood flow to centrilobular hepatocytes, fibrosis, and obstruction of hepatic blood flow; also known as veno-occlusive
disease of the liver
Although best known for their hepatotoxicity (where the bioactive metabolites, such as the dehydropyrrolic products, lead to veno-occlusive
diseases and cirrhosis), activated PAs can elicit significant genotoxicity and can be carcinogenic as well as anticarcinogenic (which has led to their experimental use in chemotherapy).
A seventh patient was reported to have died 72 days after treatment of "regimen-related veno-occlusive
disease of the liver.
Peak systolic blood flow improved in three (43%) of seven men with baseline hemodynamic impairment, and veno-occlusive
disease resolved in three (18%) of 17 individuals.